Efficacy and safety of drugs for ulcerative colitis

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 573-592

  Rosenberg, Laura Noddin ^a   Peppercorn, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

5 aminosalicylic acid; 6 mercaptopurine; anti TNF; antibiotics; azathioprine; cyclosporine; efficacy; steroids; toxicity; ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIBIOTIC AGENT; APRISO; AZATHIOPRINE; BALSALAZIDE; BETAMETHASONE DIPROPIONATE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE PSYCHOSIS; ADRENAL SUPPRESSION; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTHRITIS; ASEPTIC NECROSIS; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; EPIGASTRIC DISCOMFORT; ERYTHEMA NODOSUM; ESOPHAGITIS; FATIGUE; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; JAUNDICE; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LUNG ALVEOLITIS; LUNG TOXICITY; LUPUS LIKE SYNDROME; MENTAL DISEASE; METALLIC TASTE; MONOTHERAPY; MOTOR NEUROPATHY; MUSCULOSKELETAL PAIN; MYALGIA; MYOCARDITIS; MYOPATHY; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; OLIGOSPERMIA; OPTIC NEURITIS; OSTEOPOROSIS; OTALGIA; PAIN; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PERICARDITIS; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOTOXICITY; PREGNANCY; PROCTITIS; PRURITUS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STOMACH DISCOMFORT; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINE COLOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; COLITIS, ULCERATIVE; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953780178     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003639412     Document Type: Review

References (197)

1. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990;25(7):663-668
2. Ngo Y, Gelinet JM, Ivanovic A, et al. Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial. Gastroenterol Clin Biol 1992;16(10):782-786
3. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95(5):1263-1276
4. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95(7):1749-1754
5. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of leftsided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999;13(3):381-388
6. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40(6):775-781
7. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9(3):293-300
8. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92(10):1867-1871
9. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92(7):1143-1147
10. Rao SS, Dundas SA, Holdsworth CD, et al. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989;30(5):675-679
11. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-442
12. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54(6):1157-1170
13. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007;6(2):99-107
14. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21(12):827-834
15. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, highconcentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75, quiz 432-433
16. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twicedaily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5(1):95-102
17. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26(2):205-215
18. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54(7):960-965
19. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000543
20. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57(7):893-902
21. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100(6):1345-1353
22. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis 2007;13(10):1293-1298
23. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134(2):577-594
24. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92(3):454-456
25. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115(5):1072-1078
26. Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4(2):123-129
27. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993;7(2):155-158
28. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999;44(6):1220-1221
29. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12(4):335
30. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27(10):1210-1212
31. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89(1):43-46
32. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36(9):971-974
33. Peppercorn MA. Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 1993;17(1):14-17
34. Thukral C, Travassos WJ, Peppercorn MA. The role of antibiotics in inflammatory bowel disease. Curr Treat Option Gastroenterol 2005;8(3):223-228 (Pubitemid 40873153)
35. Lindgren S, Lofberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002;37(6):705-710
36. James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J 2008;38(2):114-119
37. Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9(5):557-562
38. Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39(4):329-337
39. Gionchetti P, D'Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a singleblind randomized controlled trial. J Clin Gastroenterol 2005;39(4):291-297
40. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;2(4884):375-378
41. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2(8099):1086-1088
42. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15(6):935-950
43. Peppercorn MA, Farrell RJ. Medical management of ulcerative colitis. In: UpToDate, Ginsburg, CH (Ed), UpToDate, Waltham, MA, 2009
44. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and leftsided ulcerative colitis. Gastroenterology 1996;110(6):1713-1718
45. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and leftsided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17(12):1471-1480
46. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16(6):1109-1116
47. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69(1):96-99
48. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982;284(6325):1291-1292
49. Karoui S, Djebbi S, Belkhodja A, et al. Maintenance therapy by azathioprine after successful treatment by intravenous corticosteroid in acute severe colitis. An open prospective study. Tunis Med 2008;86(4):322-327
50. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478
51. Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37(4):270-274
52. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99(6):1122-1128
53. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30(2):126-137
54. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277
55. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841-1845
56. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120(6):1323-1329
57. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999;5(1):1-10
58. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10(2):73-78
59. Message L, Bourreille A, Laharie D, et al. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005;29(3):231-235
60. Van Assche G, D'Haens G, Noman M, et al. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125(4):1025-1031
61. Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18(3):303-308
62. de Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005;22(3):203-208
63. Weber A, Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006;12(12):1131-1135
64. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7(Suppl 1):S30-3
65. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96(8):2373-2381
66. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroidrefractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113(23-24):930-933
67. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97(10):2577-2584
68. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an openlabel multicentre study. Aliment Pharmacol Ther 2003;18(2):175-181
69. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7(2):83-88
70. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 2005;128(7):1805-1811
71. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52(7):998-1002
72. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroidrefractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16(11):1167-1171
73. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004;8(5):231-233
74. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-2476 (Pubitemid 41770166)
75. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102(4):794-802
76. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137(4):1520
77. Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2009;3(4):395-405
78. Grimes DA, Schulz KF. Descriptive studies: what they can and cannot do. Lancet 2002;359(9301):145-149
79. Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001;358(9296):1872-1873
80. Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlledrelease mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995;30(Suppl 8):108-111
81. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19(2):179-189
82. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16(1):61-68
83. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54(6):1157-1170
84. Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazineassociated blood disorders. Pharmacotherapy 1995;15(2):176-181
85. Sachar DB. The safety of sulfasalazine: the gastroenterologists experience. J Rheumatol Suppl 1988;16:14-16
86. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51(4):536-539
87. O'Morain C, Smethurst P, Dore CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984;25(10):1078-1084
88. Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002;19(4):756-764
89. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544
90. Scherl EJ, Pruitt R, Gordon GL, et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mildto- moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104(6):1452-1459
91. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58(2):233-240
92. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009;15(1):1-8
93. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7(7):762-769
94. Kerns MJ, Mallatt BD, Shamma HN. Granulomatous pigmented purpura: an unusual histological variant. Am J Dermatopathol 2009;31(1):77-80
95. Fukunaga K, Ohda Y, Inoue T, et al. Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis. Inflamm Bowel Dis 2007;13(8):1055-1056
96. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol 2008;31(8):477-484
97. Elseviers MM, D'Haens G, Lerebours E, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol 2004;61(2):83-89
98. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126(7):1733-1739
99. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007;13(5):629-638 (Pubitemid 46799647)
100. Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23(3):170-176
101. Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40(11):1334-1342
102. Juillerat P, Pittet V, Felley C, et al. Drug safety in Crohn's disease therapy. Digestion 2007;76(2):161-168
103. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88(3):681-684
104. Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ ethanol interaction. Am J Forensic Med Pathol 1996;17(4):343-346
105. Arcieri GM, Becker N, Esposito B, et al. Safety of intravenous ciprofloxacin. A review. Am J Med 1989;87(5A):92S-7S
106. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359(18):1932-1940
107. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5(3):339-344
108. Lim S, Alam MG. Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia. Ren Fail 2003;25(4):647-651
109. Hallgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens- Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003;49(Suppl 5):S267-9
110. Mandal B, Steward M, Singh S, Jones H. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. Age Ageing 2004;33(4):405-406
111. Urbina F, Barrios M, Sudy E. Photolocalized purpura during ciprofloxacin therapy. Photodermatol Photoimmunol Photomed 2006;22(2):111-112
112. Reeves RR. Ciprofloxacin-induced psychosis. Ann Pharmacother 1992;26(7-8):930-931
113. Steiger D, Bubendorf L, Oberholzer M, et al. Ciprofloxacin-induced acute interstitial pneumonitis. Eur Respir J 2004;23(1):172-174
114. Eisele S, Garbe E, Zeitz M, et al. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. Int J Clin Pharmacol Ther 2009;47(3):165-168
115. Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to mediumdose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68(12):1833-1838
116. Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf 2002;25(8):561-582
117. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94(4):878-883
118. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11(6):954-963
119. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23(5):429-448
120. Lee DA, Taylor GM, James VH, Walker G. Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone- 21-phosphate as a retention enema. Gut 1979;20(5):349-355
121. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a doseranging study. US Budesonide enema study group. Gastroenterology 1998;115(3):525-532
122. Lofberg R, Ostergaard Thomsen O, Langholz E, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994;8(6):623-629
123. Bar-Meir S, Fidder HH, Faszczyk M, et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003;46(7):929-936
124. Danielsson A, Lofberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27(1):9-12
125. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123(2):132-142
126. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000545
127. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(1):CD000067
128. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34(8):1081-1085
129. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007;102(11):2488-2494
130. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46(3):187-208
131. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-1030
132. Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008;103(12):3115-3122
133. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118(4):705-713
134. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111(8):641-649
135. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003;37(3):220-225
136. Cassinotti A, Massari A, Ferrara E, et al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol 2007;63(9):875-878
137. Simpson CD. Azathioprine-induced pericarditis in a patient with ulcerative colitis. Can J Gastroenterol 1997;11(3):217-219
138. Paoluzi OA, Crispino P, Amantea A, et al. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet's syndrome. Case report and review of literature. Dig Liver Dis 2004;36(5):361-366
139. El-Azhary RA, Brunner KL, Gibson LE. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin Proc 2008;83(9):1026-1030
140. Yiasemides E, Thom G. Azathioprine hypersensitivity presenting as a neutrophilic dermatosis in a man with ulcerative colitis. Australas J Dermatol 2009;50(1):48-51
141. Ali M, Duerksen DR. Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can J Gastroenterol 2008;22(3):296-298 (Pubitemid 351676391)
142. Katsenos S, Psathakis K, Kokkonouzis I, et al. Drug-induced pulmonary toxicity in a patient treated with mesalazine and azathioprine for ulcerative colitis. Acta Gastroenterol Belg 2007;70(3):290-292
143. Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/ 6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41(7):682-688
144. Nagy F, Molnar T, Makula E, et al. A case of interstitial pneumonitis in a patient with ulcerative colitis treated with azathioprine. World J Gastroenterol 2007;13(2):316-319
145. Ellul P, Vella V, Vassallo M. Reversible dysgeusia attributed to azathioprine. Am J Gastroenterol 2007;102(3):689
146. Karhadkar AS, Schwartz HJ, Arora M, Dutta SK. Severe muscular weakness: an unusual adverse effect of azathioprine therapy. J Clin Gastroenterol 2006;40(7):626-628
147. Nakao K, Tsunoda A, Shimizu Y, et al. Development of hepatocellular carcinoma following treatment with 6-mercaptopurine for ulcerative colitis: investigation of chromosomal aberration by comparative genomic hybridization. Int J Clin Oncol 2005;10(4):281-284
148. Russmann S, Zimmermann A, Krahenbuhl S, et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001;13(3):287-290
149. Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14(10):1425-1431
150. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121(5):1080-1087
151. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989;47(2):293-296
152. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47(12):988-992
153. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78(1A):44-49
154. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008;168(4):378-381
155. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343(8908):1249-1252
156. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-1125
157. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis. Clin Gastroenterol Hepatol 2009;7(8):874-881
158. Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103(4):937-943
159. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-1549
160. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-885
161. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6(6):644-653
162. de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31(12):1135-1144
163. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29(3):286-297
164. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19-31
165. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58(4):501-508
166. Lichtenstein GR, Cohen R., Feagan B. Safety of infliximab and other Crohn's disease therapies: TREAT registry data with 24,575 patient-years of followup [abstract 1116]. Presentation at ACG 2008; 2008
167. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4(5):621-630
168. D'Haens G, Suenaert P, Westhovens R, Rutgeerts P. Severe knee pain as the single symptom of CMV infection in acute ulcerative colitis treated with cyclosporine. Inflamm Bowel Dis 1998;4(1):27-28
169. Piton G, Dupont-Gossart AC, Weber A, et al. Severe systemic cytomegalovirus infections in patients with steroidrefractory ulcerative colitis treated by an oral microemulsion form of cyclosporine: report of two cases. Gastroenterol Clin Biol 2008;32(5 Pt 1):460-464
170. Hibi K, Kusugami K, Ina K, et al. Disseminated intravascular coagulation associated with systemic cytomegalovirus infection during cyclosporine therapy for ulcerative colitis: report of a case. Dis Colon Rectum 2006;49(1):127-131
171. Quan VA, Saunders BP, Hicks BH, Sladen GE. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997;314(7077):363-364
172. Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum 1997;40(8):973-976
173. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med 1992;327(7):497-498
174. Caroli A, Fregonese D, Di Falco G, D'Inca R. Aspergillus fumigatus pneumonia during cyclosporine treatment for ulcerative colitis. Am J Gastroenterol 2000;95(10):3016-3017
175. Stack WA, Richardson PD, Logan RP, et al. Nocardia asteroides lung abscess in acute ulcerative colitis treated with cyclosporine. Am J Gastroenterol 2001;96(7):2255-2256
176. Hinterreiter M, Stadler B, Knoflach P. Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis. Acta Med Austriaca 2000;27(3):91-93
177. Al-Shekhlee A, Oghlakian G, Katirji B. A case of cyclosporine-induced dural sinus thrombosis. J Thromb Haemost 2005;3(6):1327-1328
178. Murata S, Ishikawa N, Oshikawa S, et al. Cerebral sinus thrombosis associated with severe active ulcerative colitis. Intern Med 2004;43(5):400-403
179. Humphreys TR, Leyden JJ. Acute reversible central nervous system toxicity associated with low-dose oral cyclosporine therapy. J Am Acad Dermatol 1993;29(3):490-492
180. Sood A, Midha V, Sood N. Reversible posterior leukoencephalopathy due to oral cyclosporine in severe ulcerative colitis. Indian J Gastroenterol 2003;22(6):233-234
181. Shibahara T, Miyazaki K, Sato D, et al. Rectal malignant lymphoma complicating ulcerative colitis treated with longterm cyclosporine A. J Gastroenterol Hepatol 2006;21(1 Pt 2):336-338
182. Schwartz LK, Kim MK, Coleman M, et al. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4(8):1030-1034
183. Rahman AH, O'Brien C, Patchett SE. Leg bone pain syndrome in a patient with ulcerative colitis treated with cyclosporin. Ir J Med Sci 2007;176(2):129-131
184. Rottenberg Y, Fridlender ZG. Recurrent infusion phlebitis induced by cyclosporine. Ann Pharmacother 2004;38(12):2071-2073
185. Beaugerie L, Carrat F, Bouvier A, et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results from the CESAME cohort. Gastroenterology 2008;134(Suppl):A116-7
186. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6(11):1212-1217, quiz 176
187. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53(6):849-853
188. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-936
189. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009;15(9):1410-1416
190. Viget N, Vernier-Massouille G, Salmon- Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57(4):549-558
191. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110(5):353-356
192. Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005;21(4):385-389
193. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110(5):1416-1421
194. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003;98(3):530-537
195. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55(9):1255-1262
196. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008;(3):CD007216
197. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118(6):1018-1024